RAS Mutation Analysis, Cell-based
Use
Activating RAS mutations occur in various human malignancies, including KRAS (e.g., in pancreatic (~80–90%) and colorectal (~30–60%) carcinomas), HRAS (non‑melanoma skin cancers ~30–50%), and NRAS (hematopoietic neoplasias ~18–30%). KRAS mutations generally signify adverse prognosis and resistance to receptor tyrosine kinase‑directed therapies, including EGFR inhibitors. Specifically, KRAS G12C has been associated with response to targeted KRAS G12C inhibitors and is a biomarker in NSCLC (~13% prevalence, comprising ~44% of KRAS variants). The assay is CLIA‑validated for clinical use but has not been cleared or approved by the FDA.
Special Instructions
Not provided.
Limitations
Not provided.
Methodology
Other
Biomarkers
HRAS, KRAS, NRAS
Gene
Result Turnaround Time
4-5 days
Related Documents
For more information, please review the documents below
Specimen
Tissue
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Submission of formalin‑fixed, paraffin‑embedded tissue is the preferred sample type.
Other tests from different labs that may be relevant